<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638781</url>
  </required_header>
  <id_info>
    <org_study_id>PN01-CLD-000001/01</org_study_id>
    <nct_id>NCT00638781</nct_id>
  </id_info>
  <brief_title>Desmoteplase in Acute Ischemic Stroke (DIAS)</brief_title>
  <official_title>Multicentre, Multinational, Double-Blind, Placebo-Controlled, Randomised Phase II Trial of Desmoteplase (INN) in the Indication of Acute Ischaemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PAION Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PAION Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DIAS study (Part 2) was performed to support the dose finding of desmoteplase treatment
      in subjects with acute ischemic stroke selected by perfusion/diffusion mismatch on MRI within
      a time window of 3 to 9 h after stroke-symptom onset. In addition, it assessed safety and
      tolerability of 3 doses of desmoteplase compared with placebo with special consideration of
      intracranial hemorrhage and major systemic bleedings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute stroke is the third leading cause of mortality in developed countries and the major
      medical cause of disability. The outcome can be improved by early treatment with
      thrombolysis. Alteplase (r-tPA) is the only approved thrombolytic drug in the indication of
      acute ischemic stroke. However, the use of alteplase is currently restricted by the need to
      administer it within 3 hours of symptom onset. As the risk of transforming a cerebral infarct
      into haemorrhage probably rises as the time elapsed increases, a thrombolytic drug that
      carries a lower risk of haemorrhage than alteplase may offer a wider time-to-treatment window
      and improve the safety profile.Desmoteplase (DSPA) with its high fibrin specificity, lack of
      neurotoxicity, potential neuroprotective effect, non-activation by ß-amyloid, and long
      terminal half-life may account for an improved safety and efficacy profile within the first 9
      hours after onset of symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS), Barthel-Index &amp; mRS</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lesion volume</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reperfusion after 4-8 h</measure>
    <time_frame>8 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and pharmacoeconomic outcomes</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Desmoteplase 62.5 µg/kg BW i.v. bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Desmoteplase 90 µg/kg BW i.v. bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Desmoteplase 125 µg/kg BW i.v. bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo i.v. bolus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmoteplase</intervention_name>
    <description>Desmoteplase 62.5 µg/kg BW</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmoteplase</intervention_name>
    <description>Desmoteplase 90 µg/kg BW</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmoteplase</intervention_name>
    <description>Desmoteplase 125 µg/kg BW</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  scoring 4 to 20 on the National Institute of Health Stroke Scale (NIHSS)

          -  showing a perfusion-diffusion mismatch on MRI of 20 %

          -  enrolment within a 3 h to 9 h time window after symptom onset.

          -  18-85 years of age

        Exclusion Criteria:

          -  Participation in any interventional trial in the previous 30 days.

          -  Women in the childbearing age.

          -  Any history of intracranial hemorrhage, subarachnoid hemorrhage, neoplasm,
             arteriovenous malformation or aneurysm.

          -  Conditions that, according to the judgment of the investigator, might impose an
             additional risk to any individual stroke patient when receiving study medication (this
             applied to patients on platelet-function inhibitors as well).

          -  MRI exclusion criteria: Evidence of ICH, Evidence of SAH, Signs of extensive early
             infarction on DWI assessed by evidence of involvement of &gt;1/3 of the middle cerebral
             artery (MCA) territory. No perfusion deficit, Internal carotid artery (ICA) occlusion
             ipsilateral to stroke lesion without additional ipsilateral MCA, anterior cerebral
             artery (ACA) or posterior cerebral artery (PCA) occlusion. Any intracranial pathology
             that would interfere with the MRI assessment of acute ischemic stroke.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Hacke, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Neurology Department, University of Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prof. Dr. Werner Hacke</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://stroke.ahajournals.org/cgi/reprint/36/1/66</url>
  </link>
  <link>
    <url>http://www.paion.de</url>
    <description>PAION Deutschland GmbH</description>
  </link>
  <results_reference>
    <citation>Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005 Jan;36(1):66-73. Epub 2004 Nov 29.</citation>
    <PMID>15569863</PMID>
  </results_reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2008</study_first_posted>
  <last_update_submitted>March 12, 2008</last_update_submitted>
  <last_update_submitted_qc>March 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Karin Wilhelm-Ogunbiyi, MD / Medical Director &amp; Head of Clinical Development</name_title>
    <organization>PAION Deutschland GmbH</organization>
  </responsible_party>
  <keyword>Acute ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salivary plasminogen activator alpha 1, Desmodus rotundus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

